Dian Diagnostics Group Co., Ltd. announced that it has received CNY 1.07475849 billion in funding
December 24, 2018
Share
On December 25, 2018, Dian Diagnostics Group Co., Ltd. (SZSE:300244) closed the transaction. The company has issued 69,428,843 A shares at a price of CNY 15.48 per share for gross proceeds of CNY 1,074,758,489.64 in the transaction. The company has paid CNY 12,782,480.04 as expenses and received CNY 1,061,976,009.60 as net proceeds.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
